|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Xanthine Oxidase Is Involved in Free Radical Production in Type 1 Diabetes
Protection by Allopurinol
1 Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain
2 Department of Endocrinology, University Clinic, Valencia, Spain
The aim of this work was to study the mechanism of free radical formation in type 1 diabetes and its possible prevention. We have found oxidation of blood glutathione and an increase in plasma lipoperoxide levels in both human type 1 diabetes and experimental diabetes. Peroxide production by mitochondria does not increase in diabetes. On the contrary, the activity of xanthine oxidase, a superoxide-generating enzyme, increases in liver and plasma of diabetic animals. The increase in plasma xanthine oxidase activity may be explained by the increase in the hepatic release of this enzyme, which is not due to nonspecific membrane damage: release of other hepatic enzymes, such as the amino transferases, does not increase in diabetes. Superoxide formation by aortic rings of rabbits increases significantly in diabetes. This is completely inhibited by allopurinol, an inhibitor of xanthine oxidase. Heparin, which releases xanthine oxidase from the vessel wall, also decreases superoxide formation by aortic rings of diabetic animals. Treatment with allopurinol decreases oxidative stress in type 1 diabetic patients: hemoglobin glycation, glutathione oxidation, and the increase in lipid peroxidation are prevented. These results may have clinical significance in the prevention of late-onset vascular complications of diabetes.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  W. S. Waring, J. A. McKnight, D. J. Webb, and S. R.J. Maxwell Uric Acid Restores Endothelial Function in Patients With Type 1 Diabetes and Regular Smokers Diabetes, November 1, 2006; 55(11): 3127 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, A. Nivorozhkin, and C. Szabo Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev., March 1, 2006; 58(1): 87 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Manuel-y-Keenoy, A. Van Campenhout, P. Aerts, J. Vertommen, P. Abrams, L. F. Van Gaal, C. Van Gils, and I. H. De Leeuw Time Course of Oxidative Stress Status in the Postprandial and Postabsorptive States in Type 1 Diabetes Mellitus: Relationship to Glucose and Lipid Changes J. Am. Coll. Nutr., December 1, 2005; 24(6): 474 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cai, J. Wang, Y. Li, X. Sun, L. Wang, Z. Zhou, and Y. J. Kang Inhibition of Superoxide Generation and Associated Nitrosative Damage Is Involved in Metallothionein Prevention of Diabetic Cardiomyopathy Diabetes, June 1, 2005; 54(6): 1829 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-D. Luo, Y.-Y. Wang, W.-L. Fu, J. Wu, and A. F. Chen Gene Therapy of Endothelial Nitric Oxide Synthase and Manganese Superoxide Dismutase Restores Delayed Wound Healing in Type 1 Diabetic Mice Circulation, October 19, 2004; 110(16): 2484 - 2493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wassmann, K. Wassmann, and G. Nickenig Modulation of Oxidant and Antioxidant Enzyme Expression and Function in Vascular Cells Hypertension, October 1, 2004; 44(4): 381 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Kelley, A. Trostchansky, H. Rubbo, B. A. Freeman, R. Radi, and M. M. Tarpey Binding of Xanthine Oxidase to Glycosaminoglycans Limits Inhibition by Oxypurinol J. Biol. Chem., September 3, 2004; 279(36): 37231 - 37234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Wright, L. A. Ginger, N. Kosila, N. D. Elkins, B. Essary, J. L. McManaman, and J. E. Repine Mononuclear Phagocyte Xanthine Oxidoreductase Contributes to Cytokine-Induced Acute Lung Injury Am. J. Respir. Cell Mol. Biol., April 1, 2004; 30(4): 479 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Creager, T. F. Luscher, F. Cosentino, and J. A. Beckman Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I Circulation, September 23, 2003; 108(12): 1527 - 1532. [Full Text] [PDF]
|
|
|
|
|
|
I. G. Obrosova, A. G. Minchenko, R. Vasupuram, L. White, O. I. Abatan, A. K. Kumagai, R. N. Frank, and M. J. Stevens Aldose Reductase Inhibitor Fidarestat Prevents Retinal Oxidative Stress and Vascular Endothelial Growth Factor Overexpression in Streptozotocin-Diabetic Rats Diabetes, March 1, 2003; 52(3): 864 - 871. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |